A 41-year-old African male with a history of hepatitis B whose disease has progressed to Childs A cirrhosis, making him at increased risk for HCC. In April 2014, ultrasound describes two masses in the liver as worrisome for hepatocellular carcinoma. Additional imaging is recommended for further evaluation of the masses. The patient’s Alpha-fetoprotein (AFP) was 13.9 at this time. CT imaging demonstrated a hypervascular mass without washout in segment 7 of the liver. The other mass seen on ultrasound was not visualized on CT. The worrisome lesion was designated LIRADs 4B because of hypervascularity, lack of washout and size greater than 2.0 cm. The percutaneous biopsy performed for further evaluation was negative for malignancy. Subsequent imaging demonstrates continued lesion growth. That, combined with the elevated AFP, suggests that the lesion is HCC despite the biopsy results. The patient was evaluated for liver transplant and subsequently placed on the transplant list. In order to maintain the patient’s eligibility for transplantation, the decision was made to have the patient undergo chemoembolization. The patient underwent a single drug eluting bead chemoembolization approximately 20 months after the initial diagnosis of the mass lesion by US. The patient’s AFP decreased from a peak of 69.9 to 5.1 (normal is less than 7.5) post treatment. He will undergo routine follow-up until transplantation. If recurrent or new lesions are found, repeat chemoembolization can be considered.